化学
药物发现
药品
组合化学
机器学习
计算生物学
人工智能
药理学
计算机科学
生物化学
医学
生物
作者
Alex T. Müller,Markus Hierl,Dominik Heer,Paul Westwood,Philippe Hartz,Bigna Wörsdörfer,Christian Krämer,Wolfgang Haap,Doris Roth,Michael Reutlinger
标识
DOI:10.1021/acs.jmedchem.5c00943
摘要
High-throughput screening (HTS) remains central to small molecule lead discovery, but increasing assay complexity challenges the screening of large compound libraries. While retrospective studies have assessed active-learning-guided screening, extensive prospective validations are rare. Here, we report the first prospective evaluation of machine learning (ML)-assisted iterative HTS in a large-scale drug discovery project. Using a mass spectrometry-based assay for salt-inducible kinase 2, we screened just 5.9% of a two million-compound library in three batches and recovered 43.3% of all primary actives identified in a parallel full HTS─including all but one compound series selected by medicinal chemists. This demonstrates that ML-guided iterative screening can significantly reduce the experimental cost while maintaining hit discovery quality. Retrospective benchmarks further showed that the ML approach outperforms similarity-based methods in hit recovery and chemical space coverage. In summary, this study highlights the potential of ML-driven iterative HTS to improve efficiency also in large-scale drug discovery projects.
科研通智能强力驱动
Strongly Powered by AbleSci AI